Sort
21,453 grants matching “tuberculosis”
Targeting NETosis for the Treatment of Tuberculosis
$628,284Christina Leigh Stallings · Washington University · R01 · FY2024 · AI
Targeting NETosis for the Treatment of Tuberculosis
$628,284Christina Leigh Stallings · Washington University · R01 · FY2025 · AI
PK-PD of combination antituberculosis therapy for suppression of drug-resistance
$628,273Tawanda Gumbo · Ut Southwestern Medical Center · R01 · FY2009 · AI
Biology and Biosignatures of Anti-Tuberculosis Treatment Response
$628,257John T Belisle · Colorado State University · U01 · FY2018 · AI
Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL)
$628,162Karen R Jacobson · Boston Medical Center · R01 · FY2021 · AI
Cell Phone Video Directly Observed Therapy to Monitor Short Course LTBI Treatment
$628,162Richard S Garfein · University Of California, San Diego · U01 · FY2017 · AI
Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL)
$628,125Karen R Jacobson · Boston Medical Center · R01 · FY2020 · AI
REGULATION OF LIPID METABOLISM IN BACTERIA
$627,872Charles O Rock · St. Jude Children'S Research Hospital · R37 · FY2008 · GM
Inhaled tigecycline therapy for pulmonary M. abscessus infections
$627,834Mercedes Gonzalez-Juarrero · Colorado State University · R01 · FY2024 · AI
A multi-disciplinary approach to the identification of host metabolic determinan
$627,819Megan Murray · Brigham And Women'S Hospital · U19 · FY2020 · AI
INH-induced lysis of the HIV opportunistic infection, M. tuberculosis
$627,577William Robert Jacobs · Albert Einstein College Of Medicine · R01 · FY2008 · AI
SIngle-saMPLE tuberculosis evaluation to facilitate linkage to care: The SIMPLE TB trial
$627,536Adithya Cattamanchi · University Of California, San Francisco · R01 · FY2019 · HL
Who are the Ultra-positive, culture-negative? Understanding the trajectories of individuals in Uganda with trace M. tuberculosis nucleic acid in sputum
$627,489Emily A Kendall · Johns Hopkins University · R01 · FY2020 · HL
Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa
$627,360Yuri F. Van Der Heijden · Vanderbilt University Medical Center · R01 · FY2024 · AI
Infectious Disease and Basic Microbiological Mechanisms
$627,226Marcia B Goldberg · Massachusetts General Hospital · T32 · FY2023 · AI
Gigapixel digital PCR in Giant Unilamellar Vesicles
$627,044Adam R. Abate · University Of California, San Francisco · R01 · FY2020 · EB
The Impact of Diabetes on TB treatment outcomes
$626,943Jonathan E Golub · Johns Hopkins University · R01 · FY2017 · AI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling
$626,816George Louis Drusano · University Of Florida · R01 · FY2011 · AI
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease
$626,433Radha Rajasingham · University Of Minnesota · R01 · FY2022 · AI
Drug targets in Mtb Gluconeogenesis
$626,426Sabine Ehrt · Weill Medical Coll Of Cornell Univ · R01 · FY2011 · AI
Transcriptome and proteome remodeling by Mycobacterium tuberculosis MazF toxins
$626,264Nancy Ann Woychik · Rbhs-Robert Wood Johnson Medical School · R01 · FY2020 · AI
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis
$626,250David R Boulware · University Of Minnesota · R01 · FY2022 · NS
Fostering resilience to psychosocial and HIV risk in Indian MSM
$625,966Steven A Safren · Massachusetts General Hospital · R01 · FY2014 · MH
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
$625,958Max O'Donnell · Columbia University Health Sciences · R01 · FY2022 · AI
Targeting the casein kinase 1 (CK1)-like kinase Yck2 in fungal pathogenesis
$625,937Leah Elizabeth Cowen · University Of Toronto · R01 · FY2022 · AI